EndoCeutics Company Description
Ending breast cancer is top priority at EndoCeutics. The trial-phase biopharmaceutical company develops hormone therapies for treating and preventing breast cancer and endocrine-related disorders affecting postmenopausal women, as well as aging men. The company specializes in phase III clinical trials and commercialization of pharmaceuticals. Its leading product candidate, acolbifene, is a selective estrogen receptor modulator (SERM) that inhibits the stimulatory effect that estrogen (a female sex hormone) has on the growth of breast and uterine cancer. Other products include DHEA for use in treatment of postmenopausal women suffering from vaginal atrophy.
View the Comprehensive Company Description for EndoCeutics
The Company Description provides a historical perspective of EndoCeutics's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of EndoCeutics's evolution in the marketplace.
